Further analyses on the 111 and 112 studies will form the basis of presentations at leading medical conferences and peer reviewed scientific publications during 2009 and 2010.
Interactions with clinical and scientific advisors
In 2008, NicOx organized 11 Advisory Boards to discuss naproxcinod's clinical results with world-famous experts in the fields of rheumatology, cardiology, nephrology and gastroenterology. Clinical advisors were consulted about various topics such as cardiovascular and blood pressure concerns related to traditional NSAIDs and COX-2 inhibitors, blood pressure and gastrointestinal results observed with naproxcinod and nitric oxide's mechanism of action.
The Company also attended 9 scientific congresses in 2008 and sponsored 3 symposia: at the American Heart Association (AHA) annual meeting in New Orleans, the European League Against Rheumatism (EULAR) annual meeting in Paris, and the Osteoarthritis Research Society International (OARSI) congress in Rome. All these events gave NicOx' scientists and clinicians the opportunity to seek advice regarding naproxcinod data from many leading advisors.
Initiation of a series of phase 1b studies by Merck & Co., Inc. in the hypertension field
In May 2008, Merck initiated a series of clinical studies in volunteers
with mild to moderate hypertension. This program is part of the March 2006
agreement to develop n
Copyright©2009 PR Newswire.
All rights reserved